Search / Trial NCT00002249

A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

Launched by R W JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE · Aug 30, 2001

Trial Information

Current as of November 03, 2024

Completed

Keywords

Anti Infective Agents, Quinolone Ofloxacin Acquired Immunodeficiency Syndrome

Description

No description provided

Gender

MALE

Eligibility criteria

  • Inclusion Criteria
  • Patients must have the following:
  • HIV infection.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • * Active opportunistic infection or neoplasm.
  • * High likelihood of death during study.
  • * Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease.
  • * Donation of \> 1 unit blood or acute loss of blood within one month of study entry.
  • Patients with the following prior conditions are excluded:
  • * History of opportunistic infection.
  • * Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone.
  • Prior Medication:
  • Excluded:
  • Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.

About R W Johnson Pharmaceutical Research Institute

The R.W. Johnson Pharmaceutical Research Institute is a leading pharmaceutical research organization dedicated to advancing innovative therapeutic solutions that improve patient outcomes. With a strong focus on drug development and clinical trials, the Institute leverages cutting-edge science and technology to discover and evaluate new treatments across a range of medical conditions. Committed to rigorous research methodologies and ethical standards, R.W. Johnson Pharmaceutical Research Institute collaborates with various stakeholders, including academic institutions and healthcare professionals, to drive progress in the pharmaceutical industry and deliver transformative therapies to patients worldwide.

Locations

Raritan, New Jersey, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials